Assessment of Potential Interactions Between GBR 12909 and Cocaine - 1
This trial is active, not recruiting.
|Sponsor||National Institute on Drug Abuse (NIDA)|
|Start date||June 2004|
|End date||June 2005|
|Trial size||24 participants|
|Trial identifier||NCT00100113, NIDA-CPU-0004-1|
The purpose of this study is to assess potential interactions between intravenous (IV) cocaine and 3 doses of GBR 12909.
Male or female participants from 18 years up to 45 years old.
Inclusion Criteria: - Must be within 20% ideal body weight and must weigh at least 45 kg. - Must understand the study procedures and provide written informed consent. - Must meet DSM-4 criteria and are non-treatment seeking at time of study. Exclusion Criteria: - Please contact study site for more information
|Official title||Study of Interactions Between GBR 12909 and Cocaine|
|Principal investigator||Kathryn Cunningham, Ph.D.|
|Description||This is Phase 1, double-blind, placebo-controlled human laboratory clinical pharmacology study that will assess the potential interactions between IV cocaine and 3 escalating oral doses of GBR 12909. The primary objective is to determine safety of GBR 12909 administration and if there are significant interactions between GBR 12909 treatment concurrent with IV cocaine infusions.|
Call for more information